![The sights of Avalon Air Show 2025: Day Three [PHOTOS]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/03/f-35-avalon-final-day-scaled-e1743079275404.jpg?#)
.jpg)
BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific
BioNTech has shown why it made small cell lung cancer a priority for its PD-L1xVEGF-A bispecific. The biotech linked BNT327 to a median overall survival of 16.8 months in a Chinese phase 2 trial, suggesting the drug candidate could set a new benchmark in a market served by AstraZeneca and Roche.
BioNTech has shown why it made small cell lung cancer a priority for its PD-L1xVEGF-A bispecific. The biotech linked BNT327 to a median overall survival of 16.8 months in a Chinese phase 2 trial, suggesting the drug candidate could set a new benchmark in a market served by AstraZeneca and Roche.
